secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001628280-22-021064
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology Q2 2022: $122M cash; preclinical ovarian data shows onvansertib + olaparib survival benefit
--------------------------------------------------------------------------------

- Cash, equivalents, and short-term investments of ~$122M as of June 30, 2022; net cash used in Q2 2022 was $6.7M, up from $4.3M in Q2 2021.
- R&D expenses rose to $7.45M from $4.12M YoY, driven by CMC and clinical pharmacology studies for onvansertib.
- Preclinical ovarian cancer data at AACR: onvansertib + olaparib showed statistically significant survival benefit vs either agent alone in three PDX models.
- Phase 2 mCRPC trial: 75% (15/20) of most dose-dense arm achieved stable disease or partial response at 12 weeks; response correlated with PTEN/MTOR mutations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000162828022021064/0001628280-22-021064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000162828022021064/crdf-20220804.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-021064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer